Skip to main content

Table 3 Survival analysis of predicting CSS and OS after IPTW-adjusted by CRT or CT in NEEC patients

From: The survival impact of adjuvant radiotherapy and chemotherapy in patients with non-endometrioid endometrial carcinomas: a PSM-IPTW analysis based on SEER database

 

Cause-specific survival

Overall survival

 

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

Characteristics

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

Adjuvant treatment

 CRT

Reference

   

Reference

   

 CT alone

1.96 (1.81–2.12)

 < 0.001

1.25 (1.14–1.37)

 < 0.001

1.90 (1.76–2.05)

 < 0.001

1.27 (1.17–1.38)

 < 0.001

Age group (years)

  < 50

Reference

   

Reference

   

 50–65

0.99 (0.77–1.26)

0.908

1.27 (0.99–1.62)

0.058

0.99 (0.78–1.25)

0.917

1.27 (1.08–1.61)

0.044

  > 65

1.16 (0.91–1.42)

0.221

1.53 (1.19–1.95)

0.001

1.25 (0.99–1.57)

0.062

1.62 (1.28–2.05)

 < 0.001

Year of diagnosis

 2004–2008

Reference

   

Reference

   

 2009–2013

0.78 (0.69–0.86)

 < 0.001

0.84 (0.76–0.94)

0.002

0.80 (0.72–0.88)

 < 0.001

0.87 (0.78–0.96)

0.006

 2014–2018

0.69 (0.62–0.76)

 < 0.001

0.726 (0.649–0.812)

 < 0.001

0.71 (0.64–0.78)

 < 0.001

0.75 (0.68–0.84)

 < 0.001

Race recode

 Black

Reference

   

Reference

   

 Othersa

0.74 (0.63–0.86)

 < 0.001

0.68 (0.58–0.80)

 < 0.001

0.76 (0.66–0.88)

 < 0.001

0.72 (0.62–0.83)

 < 0.001

 White

0.87 (0.79–0.96)

0.003

0.85 (0.77–0.93)

0.001

0.87 (0.79–0.95)

0.001

0.85 (0.80–0.93)

 < 0.001

Marital status

 Divorced/separated

Reference

   

Reference

   

 Married

0.88 (0.78–0.98)

0.026

0.95 (0.85–1.07)

0.438

0.85 (0.76–0.95)

0.005

0.93 (0.8301.04)

0.199

 Single/unmarried

1.09 (0.88–1.16)

0.915

0.97 (0.84–1.12)

0.655

0.98 (0.86–1.12)

0.794

0.96 (0.84–1.09)

0.502

 Unknown

0.76 (0.61–0.96)

0.018

0.89 (0.71–1.12)

0.310

0.81 (0.65–0.99)

0.041

0.93 (0.76–1.15)

0.516

 Widowed

1.13 (0.98–1.29)

0.095

1.018 (0.883–1.172)

0.809

1.18 (1.04–1.34)

0.012

1.06 (0.93–1.21)

0.413

Median household income

 < $50,000

Reference

   

Reference

   

 $50,000–65,000

1.01 (0.89–1.16)

0.908

1.11 (0.98–1.26)

0.115

0.98(0.87–1.11)

0.738

1.07 (0.95–1.21)

0.257

  > $65,000

0.90 (0.80–1.01)

0.077

0.99 (0.88–1.12)

0.887

0.85(0.76–0.96)

0.006

0.94 (0.84–1.05)

0.270

Grade

 I

Reference

   

Reference

   

 II

1.14 (0.70–1.86)

0.588

1.10 (0.68–1.79)

0.698

1.07 (0.70–1.64)

0.750

1.05 (0.69–1.61)

0.814

 III

1.68 (1.09–2.58)

0.019

1.42 (0.92–2.19)

0.115

1.40 (0.96–2.04)

0.076

1.20 (0.83–1.76)

0.333

 IV

1.65 (1.07–2.55)

0.023

1.38 (0.89–2.13)

0.149

1.41 (0.97–2.06)

0.073

1.20 (0.82–1.75)

0.354

 Unknown

1.52 (0.98–2.34)

0.062

1.22 (0.79–1.89)

0.381

1.31 (0.90–1.92)

0.160

1.07 (0.73–1.57)

0.715

Histology

 Clear cell

Reference

   

Reference

   

 Serous

1.12 (0.99–1.27)

0.083

1.07 (0.94–1.21)

0.322

1.08 (0.96–1.21)

0.225

1.03 (0.92–1.16)

0.610

 Carcinosarcoma

1.73 (1.47–2.03)

 < 0.001

1.90 (1.597–2.252)

 < 0.001

1.67 (1.43–1.94)

 < 0.001

1.81 (1.54–2.13)

 < 0.001

TNM stage

 T1N0M0

Reference

   

Reference

   

 T2N0M0

2.20 (1.78–2.71)

 < 0.001

2.11 (1.71–2.61)

 < 0.001

2.09 (1.73–2.537)

 < 0.001

2.02 (1.67–2.44)

 < 0.001

 T3-4aN0MO

3.74 (3.20–4.36)

 < 0.001

3.43 (2.933–4.013)

 < 0.001

3.30 (2.87–3.79)

 < 0.001

3.05 (2.64–3.52)

 < 0.001

 TanyN1M0

4.22 (3.67–4.86)

 < 0.001

4.12 (3.566–4.766)

 < 0.001

3.86 (3.40–4.38)

 < 0.001

3.78 (3.32–4.31)

 < 0.001

 TanyN2M0

5.58 (4.40–7.08)

 < 0.001

5.21 (4.082–6.648)

 < 0.001

4.78 (3.80–6.00)

 < 0.001

4.43 (3.51–5.60)

 < 0.001

 TanyNanyM1

10.62(9.32–12.10)

 < 0.001

8.02 (6.964–9.235)

 < 0.001

9.06 (8.05–10.20)

 < 0.001

6.85 (6.03–7.79)

 < 0.001

Surgery mode

 Total hysterectomy

Reference

   

Reference

   

 Extended hysterectomy

1.53 (1.37–1.71)

 < 0.001

1.14 (1.02–1.28)

0.021

1.49 (1.34–1.66)

 < 0.001

1.13 (1.06–1.26)

0.026

Lymphadenectomy

 Yes

Reference

   

Reference

   

 No

2.33 (2.15–2.53)

 < 0.001

1.47 (1.34–1.61)

 < 0.001

2.24 (2.07–2.42)

 < 0.001

1.45 (1.32–1.58)

 < 0.001

 SLN biopsy/removed

0.86 (0.69–1.07)

0.182

1.02 (0.81–1.28)

0.883

0.85 (0.70–1.05)

0.137

0.99 (0.80–1.24)

0.970

Tumor Size (mm)

  < 20

Reference

   

Reference

   

 20–39

1.30 (1.11–1.53)

0.001

1.08 (0.92–1.26)

0.378

1.31 (1.13–1.53)

 < 0.001

1.10 (0.94–1.28)

0.241

 40–59

1.72 (1.47–2.02)

 < 0.001

1.26 (1.07–1.48)

0.006

1.70 (1.46–1.97)

 < 0.001

1.24 (1.07–1.45)

0.005

 60–79

2.21 (1.87–2.63)

 < 0.001

1.27 (1.07–1.52)

0.007

2.22 (1.89–2.61)

 < 0.001

1.29(1.10–1.53)

0.002

  ≥ 80

2.80 (2.37–3.32)

 < 0.001

1.39 (1.17–1.66)

 < 0.001

2.80 (2.39–3.29)

 < 0.001

1.43 (1.21–1.69)

 < 0.001

 Unknown

1.82 (1.56–2.11)

 < 0.001

1.18 (1.01–1.37)

0.041

1.82 (1.58–2.10)

 < 0.001

1.21 (1.05–1.40)

0.010

  1. CT chemotherapy, CRT chemoradiotherapy, SLN sentinel lymph node. Race Othersa: American Indian, Asian/Pacific Islander. IPTW inverse probability treatment weighting